Ecosystem
Provast: Leading from the front gives a clear view of the road ahead
Utrecht Region: A Maturing Biotech Hub Steps Forward
2 min read
When Innovation for Health arrives in Utrecht for the first time in March 2026, it marks more than a new location on the calendar. It underscores a trend that has been building for years: Utrecht has evolved into one of the Netherlands’ most concentrated and competitive biotech ecosystems.
The region’s strength lies in the rare convergence of leading research institutions, clinical infrastructure, startups and established life sciences leaders, many embedded within a single campus environment. Ranked Europe’s most competitive region in the EU competitiveness Index, Utrecht consistently generates more knowledge output, scientific publications, patents and related economic activity than its size would suggest. This is particularly evident in Regenerative Medicine and MedTech. In a sector where breakthroughs depend on tight alignment between science, capital and clinical validation, that density matters.
This position is no coincidence. Utrecht Science Park (USP) is the largest science park in the Netherlands. It brings together more than 31,000 employees and 55,000 students, as well as over 150 organizations and R&D-driven companies. USP is also home to leading startup incubator UtrechtInc, all within walking distance. Platforms such as the U-Forward Life Sciences BreakFast further reinforce the ecosystem, providing a recurring setting where entrepreneurs, researchers and investors accelerate pilot projects and strategic partnerships. Global biotech champions like Genmab and Merus, with significant operations and research ties in the region, further anchor Utrecht on the international map, complementing high-growth local ventures.
ROM Utrecht Region actively strengthens this momentum. Through a dedicated investment fund, we support 57 portfolio companies and are involved in many venture capital transactions in the region. Biotech represents a strategic pillar within our Life Sciences & Health portfolio, accounting for one-third of LSH investments.
The ecosystem’s quality is reflected in the companies scaling in Utrecht Region, from Laigo Bio, which raised €11.5 million for its SureTAC™ targeted protein degradation platform, to Preimure, Summa Biotech, Cleara Biotech, Phlox Therapeutics, RougeTx and Dripel.
Innovation for Health’s arrival is therefore not merely symbolic. It is a signal. Utrecht is ready to translate ideas into patient impact at speed.
ROM Utrecht Region actively stands alongside the ecosystem with capital, expertise, networks and strategic direction.
